Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

• Status: Unknown status
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Women presenting with overactive bladder symptoms will be randomized to one of 3 arms (anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing, functional MRI of the brain. Cognitive testing and functional MRI will be repeated after taking their double blinded intervention for 30 days.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Baylor Research Institute
• Collaborators: International Urogynecological Association; The Methodist Hospital Research Institute; The Methodist Hospital System
• Treatments: Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-3 Receptor Agonists; Cholinergic Antagonists; Mirabegron; Solifenacin Succinate

Criteria

Inclusion Criteria:

• Female patients of age 50 to 90 years old with OAB as defined by the International Continence Society (Urgency with or without urge incontinence, usually with frequency and nocturia in the absence of urinary tract infection or other obvious pathology) who report that symptoms cause moderate problems using the PPBC.

• English-speaking and able to consent

Exclusion Criteria:

• Males are excluded to eliminate prostate pathology and urethral strictures, as well as possible bias of gender differences on fMRI.

• Subjects with moderately severe or severe depression (screening score of 15 or more) on the Personal Health Questionnaire-9 (PHQ-9)

• Subjects with moderate to severe anxiety (screening score 25-30) on the Hamilton Anxiety Rating Scale (HAM-A)

• A screening score indicating below normal cognitive function at baseline (score of 25 or less) on the montreal cognitive assessment.

• Subjects with neurologic disorders, dementia, prior cerebrovascular accident, neurogenic bladder or post-void residual greater than 250 mL

• Anticholinergics for OAB or beta 3 agonists use for treatment of OAB in the preceding six months prior to enrollment

• Pregnant or planning to become pregnant in the next six months, or current breastfeeding

• The inability to undergo MRI